Lipocine Inc (LPCN.OQ)
12 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2014||Chairman of the Board, President, Chief Executive Officer|
|47||2013||Chief Financial Officer, Executive Vice President|
|2017||Executive Vice President, Chief Commercial Officer|
|59||2014||Lead Independent Director|
- BRIEF-Lipocine says FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando
- BRIEF-Lipocine Inc Q3 loss per share $0.22
- BRIEF-Lipocine says FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018
- BRIEF-Lipocine Inc files for mixed shelf of up to $150 million
- BRIEF-Lipocine - PTAB of USPTO issued a motions decision in interference case between Clarus Therapeutics and Lipocine Inc